Core Viewpoint - The announcement by the National Medical Products Administration regarding the optimization of clinical trial review and approval for innovative drugs is a significant positive development for the industry, particularly as it reduces the review time from 60 to 30 working days for innovative drug applications, including traditional Chinese medicine (TCM) [1] Group 1: Industry Overview - The recognition of TCM as an essential part of innovative drugs contrasts with the capital market's perception, which has not seen significant growth in TCM companies despite a surge in innovative drug stocks this year [1] - The modernization of TCM is gaining traction, supported by national policies, emphasizing the integration of traditional advantages with modern scientific techniques [3][4] Group 2: Company Profile - Yiling Pharmaceutical - Yiling Pharmaceutical is a leading innovative drug company with a focus on TCM, biopharmaceuticals, and health products, with TCM being the primary revenue and profit contributor [1] - As of the end of 2024, Yiling Pharmaceutical holds 17 patented TCM products covering eight major clinical disease systems, leading in the cardiovascular and respiratory disease treatment sectors [1] Group 3: Financial Performance - In 2024, Yiling Pharmaceutical's revenue from cardiovascular drugs exceeded 3.8 billion, while respiratory drugs accounted for less than 800 million, together representing over 70% of total revenue [9] - The company has experienced a decline in revenue over the past two years, primarily due to a significant drop in demand for its product Lianhua Qingwen post-pandemic [11] Group 4: Research and Development - Yiling Pharmaceutical has consistently ranked among the top in R&D investment within the A-share TCM sector, with annual R&D expenditures of approximately 895 million, 935 million, and 908 million over the past three years, representing 7.15%, 9.06%, and 13.94% of revenue respectively [5] - The company has achieved notable academic breakthroughs, including a landmark study published in a top medical journal demonstrating the efficacy of its product Tongxinluo in reducing cardiovascular events [6] Group 5: Growth Potential - Yiling Pharmaceutical's core competitive advantage lies in its founder's innovative theory on vascular diseases, which has attracted international research interest [12] - The company has five new drugs approved in the past five years, with four included in the medical insurance directory, indicating a strong pipeline for future growth [12] - The current market valuation of Yiling Pharmaceutical is estimated to be around 300 billion, with potential for significant appreciation as the market begins to recognize the value of innovative TCM [16]

端午节不仅是祈福消灾的传统节日，还蕴藏着丰富的养生智慧。吃粽子，赛龙舟，戴香囊，挂艾草，自古以来人们便会通过多种习俗在端午节守护健康，现 代人更是将端午节视为向长辈赠送健康礼物的好时机。从端午节的礼尚往来，可以一瞥国人对健康、衰老的认知和理解。正因如此，端午节也成为反映现代 人养生文化变迁的窗口。 图片来源：Pexels 端午送礼有新变化，长辈偏爱抗衰礼物 如今80后、90后的长辈们大多经历过中国经济起步的阶段，那时人们的生活并不富裕，也没有树立起较强的健康意识，在端午节等重要节日走亲访友时，粽 子、烟、酒、茶是最能彰显心意和诚意的礼物。而在生活富足的当下，人们的健康意识逐渐提升，对健康愈发重视。麦肯锡2024年发布的《未来健康调研》 显示，与英美相比，中国消费者对健康的重视程度更高；在中国，62%的消费者将健康视为日常生活的头等要事。 这份对健康的关注也体现在端午节等重要节日的礼尚往来里。端午节前夕，各类口服补剂和中医药抗衰产品等，在各大主流平台中的搜索热度都直线上升。 例如，在健康类产品销量中表现亮眼的抗衰中成药八子补肾，就是端午节的热门送礼之选。其中有不少是消费者买来送给长辈的。 国际期刊发表的近二十篇 ...

Group 1 - The 2025 World Brand Moganshan Conference was held in Deqing County, Zhejiang Province, focusing on the theme "Brand Makes the World Better," attracting over 4,000 leaders from politics, business, and academia [1] - The conference showcased the latest research achievements in traditional Chinese medicine (TCM) for anti-aging, particularly the Ba Zi Bu Shen natural anti-aging product, highlighting its significant breakthroughs in innovation and development [1] Group 2 - A review published in the journal "Cell" expanded the biological markers of aging from twelve to fourteen, including changes in the extracellular matrix and psychosocial isolation [3][5] - The Ba Zi Bu Shen product, developed under TCM principles, offers a systematic, multi-pathway approach to anti-aging, aligning with Western theories while maintaining its unique TCM perspective [5] - Research has shown that Ba Zi Bu Shen can intervene in ten biological aging markers by reducing senescent cells, maintaining mitochondrial homeostasis, and preserving stem cell vitality [5] Group 3 - A study published in "Biomedicine & Pharmacotherapy" demonstrated that Ba Zi Bu Shen could reverse DNA methylation patterns in aging mice, effectively reducing their biological age [6] - A clinical study published in "Phytomedicine" involving 530 participants aged 30 to 80 showed that Ba Zi Bu Shen significantly increased telomerase activity by 76.7%, indicating reduced aging effects [9] - The development of Ba Zi Bu Shen represents a successful integration of traditional TCM theories with modern scientific practices, enhancing the international reputation of TCM [9] Group 4 - The global trend indicates that Chinese brands are transitioning from "followers" to "leaders," actively participating in international markets and promoting cultural exchange [9] - The future of TCM brands like Ba Zi Bu Shen is expected to contribute significantly to global health, creating a bright path for human well-being [9]